SCHEMBL24717543

SCHEMBL24717543

O[C@H]1C[C@H](N2CCN(CC3CCNCC3)CC2)C1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.43
CACNA2D1 P54289 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNB1 Q02641 1/20 0.40
KDM4E B2RXH2 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CHRM5 P08912 1/20 0.33
ADRA2C P18825 1/20 0.33
AXL P30530 1/20 0.33
FLT3 P36888 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
ARG1 P05089 1/20 0.32
ARG2 P78540 1/20 0.32
LMNA P02545 1/20 0.31
CYP2C9 P11712 1/20 0.31
ACHE P22303 2/20 0.30
HTR4 Q13639 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22907051 0.86 GBA1 (0.47) GBA1CACNA2D1CACNA1BCACNB1CHRM5
SCHEMBL3309077 0.80 CHRM5 (0.39) GBA1CACNA2D1CACNA1BCACNB1KDM4E
SCHEMBL14422030 0.80 GBA1 (0.48) GBA1CACNA2D1CACNA1BCACNB1CHRM5
SCHEMBL24717541 0.80 CACNA2D1 (0.35) GBA1CACNA2D1CACNA1BCACNB1CHRM5
SCHEMBL5648979 0.78 GBA1 (0.50) GBA1CACNA2D1CACNA1BCACNB1CHRM5
Hydrochloric Acid SCHEMBL5573130 0.78 GBA1 (0.47) GBA1CACNA2D1CACNA1BCACNB1CHRM5
SCHEMBL27350242 0.77 CHRM5 (0.50) GBA1CACNA2D1CACNA1BCACNB1KDM4E
SCHEMBL24802104 0.77 GBA1 (0.40) GBA1CACNA2D1CACNA1BCACNB1KDM4E
SCHEMBL24802285 0.77 CACNA2D1 (0.37) GBA1CACNA2D1CACNA1BCACNB1KDM4E
SCHEMBL25026645 0.75 KMT2A (0.42) GBA1CACNA2D1CACNA1BCACNB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 GBA1 2636/4885CACNA2D1 4647/4885CACNA1B 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.